Panacea Life Sciences Hldgs Inc Stock Price, News & Analysis

Panacea Life Sciences (OTCQB:PLSH) has launched its new Calmolyte CBD Horse Paste, targeting the growing equine segment of the CBD pet market. With the market projected to grow at a 58.9% CAGR from 2021 to 2028, this product aims to alleviate everyday stress and inflammation in horses. The paste contains 1000mg of CBD, vitamins, and minerals to support hydration and recovery. Developed in collaboration with veterinarians, it reflects significant R&D efforts and aligns with consumer demand for natural health solutions.

Panacea Life Sciences (OTCQB:PLSH) announces a partnership with Chanelle McCoy Health to launch Ultra Pure CBD products in the U.S. market. This collaboration aims to provide consumers with certified CBD products backed by clinical studies, focusing on safety and efficacy. Pureis^®, the brand of Chanelle McCoy Health, is the first CBD food supplement with formal safety studies. The U.S. market launch is anticipated in Spring 2022, targeting a growing market projected to reach $39 billion by 2032.

Panacea Life Sciences, Inc. (OTCQB:PLSH) has expanded its skincare line with innovative CBD and CBG products aimed at addressing skin issues like acne, eczema, and psoriasis. The skincare market is projected to reach USD 1295.7 million by 2026, with an anticipated CAGR of 33%. The new dermatologist-approved products incorporate all-natural ingredients and are designed to meet rising consumer demand for clean, effective skincare solutions. Panacea's offerings include the Skin Clearing Gel and Derma Soothe CBD+CBG oil, targeting various skin conditions while leveraging the growing CBD market.

Panacea Life Sciences (OTCQB:PLSH) launched a new high-potency product, the 3300mg Cannabidiol Oral Solution, aimed at consumers requiring higher doses of cannabidiol (CBD) for health benefits. Priced at $0.03 per milligram, it offers a cost-effective alternative compared to similar products. Made from locally sourced hemp, this tincture is THC-Free and manufactured under strict quality controls to ensure safety and efficacy. This launch aligns with Panacea's commitment to enhancing the health and wellbeing of people and pets through purposeful cannabinoid formulations.

Panacea Life Sciences (OTCQB:PLSH) announced the launch of its premium CBD and CBG product line in Brazil through a partnership with MyPharma2Go. This collaboration aims to provide high-quality cannabinoid products to healthcare providers and consumers across Brazil, with plans for expansion into other Latin American countries. MyPharma2Go has served over 240,000 patients in Brazil and believes Panacea's rigorous quality standards will enhance their offerings. The company aims to build trust in the Brazilian market similarly to its loyal customer base in the U.S.

Panacea Life Sciences Holdings (OTCQB:PLSH) has launched new CBDA Oil Drops containing Vitamin D and Zinc, now available for purchase at Panacealife.com. Supported by recent studies from Oregon State University and the University of Chicago, these products may enhance immune responses against viral infections by blocking viral entry and replication. The Company aims to expand research on cannabinoids at their Cannabinoid Research Center at Colorado State University. This launch follows the trend of increasing demand for cannabinoid-based health products.

Panacea Life Sciences (OTCQB:PLSH) announced an exclusive partnership with Bright Ideas Unlimited to launch its hemp extract products on Amazon. This agreement enables Panacea to reach a broader audience through the Amazon marketplace, offering a range of products including gummies, tinctures, and skincare items. With a focus on quality and effective marketing strategies, both companies aim to capitalize on the growing demand for natural hemp products following the Farm Bill of 2018. This partnership positions Panacea to leverage Amazon's vast platform for increased product visibility and sales.

Panacea Life Sciences Holdings, Inc. (OTCQB:PLSH) has launched a new immunity-enhancing product, COVID CBDA™, aimed at combating COVID-19. A recent study by Oregon State University suggested that cannabinoids CBDA and CBGA may inhibit the virus's ability to infect human cells. The product is designed to provide a natural alternative to traditional pharmaceuticals and contains additional immunity-boosting ingredients. The company aims to enhance its research efforts and conduct further human clinical trials, emphasizing its commitment to developing cannabinoid-based health solutions.

Panacea Life Sciences, Inc. (OTCQB:PLSH) has partnered with MyPharma2Go to enter Brazil's cannabis market. This collaboration aims to enhance MyPharma2Go's offerings by delivering premium cannabis products. Founded in 2017, MyPharma2Go has supported over 240,000 patients across Brazil. According to their CEO, the partnership aligns with their goal of top-tier service. Panacea's Executive VP, Nick Cavarra, stated that this partnership provides access to Brazil's large consumer base, potentially increasing revenues and shareholder value in 2022.